Literature DB >> 29448503

Construction and Characterization of Cell-Penetrating Peptide-Fused Fibroblast Growth Factor and Vascular Endothelial Growth Factor for an Enhanced Percutaneous Delivery System.

Sang Won Choi1, Rudra Pangeni1, Dai Hyun Jung2, Su Jung Kim2, Jin Woo Park1.   

Abstract

The exogenous administration of growth factors has been examined for treating wounds and such factors serve as cosmetic agents for skin regeneration. However, the topical application of growth factors is hampered by their limited percutaneous absorption. In this study, we genetically modified basic fibroblast growth factor (bFGF) and vascular endothelial growth factor-A (VEGF-A) using a cell-penetrating peptide to facilitate their permeation into skin and to avoid multiple steps in the chemical or physical modification of biomaterials. Low-molecular-weight protamine (LMWP)-fused bFGF and VEGF-A (LMWP-bFGF and LMWP-VEGF-A) were designed by serial polymerase chain reaction (PCR)-mediated addition of the LMWP codons onto the bFGF and VEGF-A genes and then produced in Escherichia coli. The purified LMWP-bFGF and LMWP-VEGF-A represented >90% of the total proteins, as determined by SDS-PAGE and densitometric quantification, and their actual molecular weights, determined by mass spectroscopy, were 19,026 and 15,715 Da, respectively, corresponding to the theoretical values. N-terminal amino acid sequencing analyses confirmed the N-terminal conjugation of LMWP to bFGF and VEGF-A. Immunoblotting analyses using antibodies against bFGF and VEGF-A, together with the proliferative effects of LMWP-bFGF and LMWP- VEGF-A on human keratinocytes and fibroblasts, demonstrated that the original biological activity of each growth factor was not altered by LMWP conjugation. In addition, the LMWP conjugation did not induce further cytotoxic effects on the skin cells, while the cell membrane-penetrating activities of LMWP-bFGF and LMWP-VEGF-A were significantly enhanced compared with the respective unconjugated growth factors. These results suggest that LMWP-bFGF and LMWP-VEGF-A can be used as effective topical therapeutic or cosmetic agents for skin regeneration and anti-aging treatments.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29448503     DOI: 10.1166/jnn.2018.14864

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  3 in total

1.  Preparation and in vivo evaluation of a topical hydrogel system incorporating highly skin-permeable growth factors, quercetin, and oxygen carriers for enhanced diabetic wound-healing therapy.

Authors:  Jun-Pil Jee; Rudra Pangeni; Saurav Kumar Jha; Youngro Byun; Jin Woo Park
Journal:  Int J Nanomedicine       Date:  2019-07-18

2.  Effective production of human growth factors in Escherichia coli by fusing with small protein 6HFh8.

Authors:  Young Su Kim; Hye-Jeong Lee; Man-Ho Han; Nam-Kyung Yoon; Yeu-Chun Kim; Jungoh Ahn
Journal:  Microb Cell Fact       Date:  2021-01-07       Impact factor: 5.328

Review 3.  Strategies for efficient production of recombinant proteins in Escherichia coli: alleviating the host burden and enhancing protein activity.

Authors:  Zi-Xu Zhang; Fang-Tong Nong; Yu-Zhou Wang; Chun-Xiao Yan; Yang Gu; Ping Song; Xiao-Man Sun
Journal:  Microb Cell Fact       Date:  2022-09-15       Impact factor: 6.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.